StockData

Cosmos Health vs DataMeds AI

COSM and MEDS side by side, both in wholesale trade-non-durable goods. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How COSM and MEDS compare

Cosmos Health is the larger company, worth 146 times as much as DataMeds AI ($287M against $2.0M).

Cosmos Health grew revenue faster over the last twelve months (33.8% versus −77.5% for DataMeds AI).

Cosmos Health keeps more of each dollar of sales as profit, with a net margin of −33.1% compared with −565% at DataMeds AI.

Cosmos Health scores higher on the StockData Score (4 against 1 for DataMeds AI), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCOSMMEDS
Size and price
Market cap$287M$2.0M
Share price$2.85$0.640
Change, 1 year295%−98.0%
Change, 5 years−99.8%–
Beta (5Y)–0.34
Employees16335
StockData Score
Total score4 (better)1
Valuation score01 (better)
Growth score2 (better)0
Performance score00
Health score2 (better)0
Dividend score00
Valuation
P/S3.9×0.3× (better)
P/B13.9×–
FCF yield−3.5%–
Fair value$1.38–
Margin of safety−107%–
Growth
Revenue growth (TTM)33.8% (better)−77.5%
Revenue growth, 5Y average3.3%–
Profitability
Gross margin10.3% (better)−92.1%
Operating margin−24.9% (better)−548%
Net margin−33.1% (better)−565%
FCF margin−13.5%–
Return on equity−104% (better)−1707%
Return on invested capital−60.9% (better)−153%
Financial health
Debt / equity0.06–
Interest coverage−7.8×−6.2× (better)
Current ratio1.05 (better)0.14
Altman Z-score1.23 (better)−8.90
Piotroski F-score5 (better)1
Dividends and buybacks
Buyback yield−2.9%–
Shareholder yield−2.9%0.00% (better)
Ownership
Held by institutions2.1%1.7%
Held by insiders17.4%–
Insider net buying, 12 months$1.6M–
Short interest, % of float2.1%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.